Merck KGaA

Factors to consider:

• Company pays dividends (annually): last record date 2026-04-28, amount 2.58$ (Y1.64%)
• Price in estimated range
• Earnings for 6 months up through Q2 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

• 2025-12-31 to 2026-12-31 estimated range: [112.52$, 168.07$]
• 2026-12-31 to 2027-12-31 estimated range: [113.94$, 170.32$]

Financial Metrics affecting the MKGAF estimates:

• Negative: with PPE of 16.3 at the end of fiscal year the price was high
• Positive: 15.80 < Operating profit margin, % of 19.26
• Positive: 6.77 < Operating cash flow per share per price, % of 7.36
• Positive: 3.48 < Return on assets ratio (scaled to [-100,100]) of 4.78
• Positive: 49.86 < Shareholder equity ratio, % of 54.88 <= 58.56
• Positive: Inventory ratio change, % of -0.41 <= -0.37
• Negative: negative Industry operating cash flow (median)
• Positive: Interest expense per share per price, % of 0.49 <= 0.75
• Positive: -11.23 < Investing cash flow per share per price, % of -7.98
• Positive: Industry inventory ratio change (median), % of -0.31 <= 0